Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Entrada Shares Climb After FDA Removes Hold on Muscular Dystrophy Treatment
Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...
Le Lézard23m
OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced the formation of subsidiary OS Drug Conjugates (OSDC) ...
Le Lézard42m
NeoGenomics to Participate in Upcoming Investor Conferences
NeoGenomics, Inc. ("NeoGenomics" or the "Company") , a leading oncology testing services company, today announced the Company will participate in the following investor conferences: TD Cowen 45th ...